1. Benson, S. C., Pershadsingh, H. A., Ho, C. I., Chittiboyina, A., Desai, P., Pravenec, M., Qi, N., Wang, J., Avery, M. A., and Kurtz, T. W., Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-modulating activity. Hypertension, 43, 993–1002 (2004).
2. Chauhan, B., Shimpi, S., and Paradkar, A., Preparation and evaluation of glibenclamide-polyglycolized glycerides solid dispersions with silicon dioxide by spray drying technique. Eur. J. Pharm. Sci., 26, 219–230 (2005).
3. FDA, Guidance for industry: immediate release solid oral dosage forms — scale-up and postapproval changes: chemistry, manufacturing, and controls; in vitro dissolution testing, and in vivo bioequivalance documentation. In research, C. F. D. E. A. (Ed.). Rockville, MD (November, 1995).
4. FDA, Center for drug evaluation and research,guidance for industry: dissolution testing of immediate release solid oral dosage forms. In research, C. F. D. E. A. (Ed.). Rockville, MD (August, 1997a).
5. FDA, Center for drug evaluation and research, guidance for industry: supac-mr: modified release solid oral dosage forms — scale-up and postapproval changes: chemistry, manufacturing, and controls; in vitro dissolution testing, and in vivo bioequivalance documentation. In research, C. F. D. E. A. (Ed.). Rockville, MD (September, 1997b).